Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 6/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901357 | 1.00 | CYP11B2 (0.38) | CYP11B2CYP11B1KCNH2AOC3IDO1 | |
| SCHEMBL8258510 | 0.87 | CCR5 (0.38) | CYP11B2CYP11B1KCNH2AOC3IDO1 | |
| SCHEMBL4902105 | 0.80 | CYP11B2 (0.40) | CYP11B2CYP11B1KCNH2AOC3IDO1 | |
| SCHEMBL4902112 | 0.80 | CYP11B2 (0.40) | CYP11B2CYP11B1KCNH2AOC3IDO1 | |
| SCHEMBL6167224 | 0.77 | CCR5 (0.42) | CYP11B2KCNH2AOC3CCR5CYP2D6 | |
| SCHEMBL4011538 | 0.77 | CCR5 (0.42) | CYP11B2KCNH2AOC3CCR5CYP2D6 | |
| SCHEMBL6167230 | 0.77 | CCR5 (0.42) | CYP11B2KCNH2AOC3CCR5CYP2D6 | |
| SCHEMBL4011542 | 0.77 | CCR5 (0.42) | CYP11B2KCNH2AOC3CCR5CYP2D6 | |
| SCHEMBL8255904 | 0.76 | CYP11B2 (0.36) | CYP11B2CYP11B1KCNH2AOC3IDO1 | |
| SCHEMBL4711526 | 0.72 | AOC3 (0.44) | CYP11B2CYP11B1KCNH2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | CYP11B2 278/4885CYP11B1 334/4885KCNH2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.